Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3809894 | 0.90 | PPARA (0.56) | L3MBTL1FFAR1RXRARXRBLMNA | |
| SCHEMBL27115197 | 0.89 | L3MBTL1 (0.54) | L3MBTL1MMP2FFAR1TSHRRXRA | |
| SCHEMBL21077542 | 0.89 | L3MBTL1 (0.54) | L3MBTL1MMP2FFAR1TSHRRXRA | |
| SCHEMBL7045198 | 0.89 | PPARA (0.63) | L3MBTL1FFAR1PPARAPLA2G4B | |
| SCHEMBL3160657 | 0.87 | PPARA (0.61) | L3MBTL1FFAR1PPARAPLA2G4B | |
| SCHEMBL3170883 | 0.87 | PPARA (0.61) | L3MBTL1FFAR1PPARAPLA2G4B | |
| SCHEMBL8113416 | 0.82 | L3MBTL1 (0.46) | L3MBTL1RXRARXRBLTA4HAPP | |
| SCHEMBL2468006 | 0.82 | L3MBTL1 (0.69) | L3MBTL1MMP2FFAR1TSHRLMNA | |
| SCHEMBL38674 | 0.81 | L3MBTL1 (0.68) | L3MBTL1MMP2FFAR1TSHRLMNA | |
| SCHEMBL2234098 | 0.80 | PKM (0.69) | L3MBTL1MMP2TSHRPPARAPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112543764-B | Amide compound with BET proteolytic induction effect and medical application thereof | 田边三菱制药株式会社 | 2024-05-10 | — | — | CN | disclosed |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-16 | — | — | US | disclosed |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-16 | — | — | US | disclosed |
| EP-3819305-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-05-12 | — | — | EP | disclosed |
| WO-2020009176-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | 田辺三菱製薬株式会社 | 2020-01-09 | — | — | WO | disclosed |
| EP-0874808-B1 | BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-0874808-A1 | BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | Abbott Laboratories (US) | 1998-11-04 | — | — | EP | disclosed |
| US-5665777-A | ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1997-09-09 | — | — | US | disclosed |
| WO-1997018188-A1 | BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | BET1, BRD4, PHKB | L3MBTL1 1410/4885MMP2 514/4885FFAR1 4563/4885 |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | BET1, BRD4, PHKB | L3MBTL1 1414/4885MMP2 521/4885FFAR1 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.